Vertex Pharmaceuticals Inc (VRTX) — Cash Flow-to-Debt Ratio
Vertex Pharmaceuticals Inc (VRTX) has a Cash Flow-to-Debt Ratio of 0.20x as of March 2026, meaning its operating cash flow of $1.43 Billion could theoretically repay 0% of its total liabilities ($7.12 Billion) in one year. See VRTX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vertex Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1991–2025)
Historical debt coverage capacity for Vertex Pharmaceuticals Inc across 35 annual periods. Also explore VRTX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Vertex Pharmaceuticals Inc (1991–2025)
Year-by-year debt coverage analysis for Vertex Pharmaceuticals Inc. For market capitalisation and broader financial context, see VRTX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | $3.63 Billion | $7.48 Billion | ▲ +703.8% |
| 2024 | -0.08x | $-492.60 Million | $6.12 Billion | ▼ -111.7% |
| 2023 | 0.69x | $3.54 Billion | $5.15 Billion | ▼ -29.5% |
| 2022 | 0.97x | $4.13 Billion | $4.24 Billion | ▲ +22.8% |
| 2021 | 0.79x | $2.64 Billion | $3.33 Billion | ▼ -25.3% |
| 2020 | 1.06x | $3.25 Billion | $3.06 Billion | ▲ +51.1% |
| 2019 | 0.70x | $1.57 Billion | $2.23 Billion | ▲ +0.2% |
| 2018 | 0.70x | $1.27 Billion | $1.81 Billion | ▲ +24.9% |
| 2017 | 0.56x | $844.94 Million | $1.50 Billion | ▲ +270.2% |
| 2016 | 0.15x | $236.10 Million | $1.56 Billion | ▲ +158.3% |
| 2015 | -0.26x | $-365.43 Million | $1.40 Billion | ▲ +37.2% |
| 2014 | -0.41x | $-513.20 Million | $1.24 Billion | ▼ -673.5% |
| 2013 | -0.05x | $-51.57 Million | $962.64 Million | ▼ -130.5% |
| 2012 | 0.18x | $267.84 Million | $1.52 Billion | ▲ +51.4% |
| 2011 | 0.12x | $143.74 Million | $1.24 Billion | ▲ +122.3% |
| 2010 | -0.52x | $-635.44 Million | $1.22 Billion | ▼ -4.5% |
| 2009 | -0.50x | $-427.59 Million | $859.14 Million | ▼ -63.0% |
| 2008 | -0.31x | $-226.48 Million | $741.61 Million | ▲ +60.1% |
| 2007 | -0.76x | $-252.48 Million | $330.18 Million | ▼ -1314.1% |
| 2006 | -0.05x | $-22.48 Million | $415.64 Million | ▲ +90.3% |
| 2005 | -0.56x | $-172.05 Million | $309.82 Million | ▼ -99.2% |
| 2004 | -0.28x | $-142.16 Million | $510.01 Million | ▲ +11.6% |
| 2003 | -0.32x | $-167.62 Million | $531.57 Million | ▼ -73.3% |
| 2002 | -0.18x | $-79.54 Million | $437.14 Million | ▼ -913.6% |
| 2001 | -0.02x | $-8.07 Million | $449.78 Million | ▲ +53.9% |
| 2000 | -0.04x | $-16.64 Million | $427.12 Million | ▲ +97.2% |
| 1999 | -1.37x | $-31.80 Million | $23.21 Million | ▲ +11.5% |
| 1998 | -1.55x | $-31.10 Million | $20.10 Million | ▼ -222.6% |
| 1997 | -0.48x | $-9.40 Million | $19.60 Million | ▲ +84.9% |
| 1996 | -3.17x | $-40.30 Million | $12.70 Million | ▼ -171.7% |
| 1995 | -1.17x | $-16.00 Million | $13.70 Million | ▲ +15.0% |
| 1994 | -1.37x | $-14.70 Million | $10.70 Million | ▼ -283.7% |
| 1993 | 0.75x | $8.60 Million | $11.50 Million | ▲ +200.2% |
| 1992 | -0.75x | $-5.30 Million | $7.10 Million | ▼ -46.3% |
| 1991 | -0.51x | $-2.50 Million | $4.90 Million | — |